Friday, June 1, 2018 @ 12:00 am
Santersus SA (Switzerland), a privately held innovative plasmapheresis start-up company, announces the beginning of plasmapheresis prototype development using its revolutionary intellectual property.
“This is a very important practical step in taking our best-of-class technology to the next level” said Dmitry D. Genkin, M.D. co-founder of Santersus SA. “At Santersus, we strive to become a leading plasmaphersis company by creating universal solutions with a profound therapeutic impact.”